Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~Patients with CVID (Common Variable Immunodeficiency) or XLA (X-linked agammaglobulinemia) who:~Participated in the Phase III clinical study with intravenous IgPro10 (study number ZLB03_002CR) at 3- or 4- weekly intervals for 12 months (referred to as 'old' subjects)~OR~Were ≥ 6 years of age, were on other stable intravenous immunoglobulin therapy (200-800 mg IgG per kg body weight) at 3- or 4-week intervals for at least 6 months, AND were interested in participating in the Phase III clinical study with subcutaneous IgPro20 (study number ZLB04_009CR) (referred to as 'new' subjects)~Written informed consent~Key Exclusion Criteria:~Diagnosis of epilepsia~Insulin dependent diabetes~Administration of steroids (daily ≥ 0.15 mg prednisone equivalent/kg/day) or other immunosuppressive drugs~History of cardiac insufficiency (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 71 Years
- Healthy Volunteers: f

Study Arms:
- IgPro10 (Type: EXPERIMENTAL): See Intervention Description

Based on this trial design, predict the completion outcome and termination type (if applicable).